Sagittarius A-Star
Science Advisor
- 1,378
- 1,045
PeroK said:The logic is to focus on the long-term benefits of the 12 week gap, but given the rise in cases, I would have thought tackling the Delta outbreak would be the priority.
The German STIKO (Standing Committee on Vaccination) recommends now (because of the delta variant) for persons, who got the first shot with AstraZeneka-vaccine, to get the second shot minimum 4 weeks later with Biontech/Pfizer or Moderna (mRNA vaccine):
https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2021-07-01.html
Related press release of the Oxford University:
Source:Oxford press release said:Of note is that the order of vaccines made a difference, with an Oxford-AstraZeneca/Pfizer-BioNTech schedule inducing higher antibodies and T-cell responses than Pfizer-BioNTech/Oxford-AstraZeneca, and both of these inducing higher antibodies than the licensed, and highly effective ‘standard’ two-dose Oxford-AstraZeneca schedule. The highest antibody response was seen after the two-dose Pfizer-BioNTech schedule, and the highest T cell response from Oxford-AstraZeneca followed by Pfizer-BioNTech.
https://www.ox.ac.uk/news/2021-06-2...generate-robust-immune-response-against-covid
A preliminary study shows a high number of antibodies and T-cells from the hybrid vaccination scheme.
Source:preliminary Oxford paper said:Abstract
Adults ≥ 50 years, including those with well-controlled comorbidities, were randomised across eight groups to receive ChAd/ChAd, ChAd/BNT, BNT/BNT or BNT/ChAd, administered at 28- or 84-day intervals.
...
In conclusion, our study confirms the heterologous and homologous schedules of ChAd and BNT can induce robust immune responses with a 4-week prime boost interval.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3874014